Article
Randomized phase 2 study of tivantinib plus erlotinib versus single-agent chemotherapy in previously treated KRAS mutant advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) - 1 Mar 2018
Gerber David E, Socinski Mark A, Neal Joel W, Wakelee Heather A, Shirai Keisuke, Sequist Lecia V, Rosovsky Rachel P, Lilenbaum Rogerio C, Bastos Bruno R, Huang Chao, Johnson Melissa L, Hesketh Paul J, Subramaniam Deepa S, Dietrich Martin F, Chai Feng, Wang Yunxia, Kazakin Julia, Schwartz Brian, Schiller Joan H, Brahmer Julie R, Kelly Ronan J
Abstract excerpt
BACKGROUND: KRAS mutations are identified in approximately 25% of non-small cell lung cancer (NSCLC) cases and are associated with resistance to currently available targeted therapies. The MET oncogene may be implicated in malignant progression of KRAS-mutant tumors. In a pre-specified subset analysis of KRAS mutant cancers in an earlier phase 2 study of erlotinib plus the oral MET inhibitor tivantinib,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.